Trials / Unknown
UnknownNCT04738630
Study of HX008 for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer
A Single-arm, Open-lable, Multicenter, Phase II Clinical Study of HX008 in Subjects With BCG-Unresponsive Non-muscle Invasive Bladder Cancer
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 110 (estimated)
- Sponsor
- Taizhou Hanzhong biomedical co. LTD · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a single-arm, multicenter study to evaluate the efficacy and safety of HX008 injection in patients with BCG-unresponsive non-muscle invasive bladder cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | HX008 | 200 mg administered as IV infusion on Day 1 of each 21-day cycle. |
Timeline
- Start date
- 2020-09-25
- Primary completion
- 2022-12-01
- Completion
- 2023-12-01
- First posted
- 2021-02-04
- Last updated
- 2021-02-04
Locations
5 sites across 1 country: China
Source: ClinicalTrials.gov record NCT04738630. Inclusion in this directory is not an endorsement.